|
|
InNexus Biotechnology Inc. (IXS) |
|
|
|
CEOCFO Current
Issue |
This is a printer friendly page! InNexus
Biotechnology’s SuperAntibodies
is the only alternative for biotechs and pharmaceuticals not wanting to use toxic agents
to increase the potency of their antibodies InNexus Biotechnology Inc. (Toronto: Venture - IXS)
is developing the next generation of therapeutic, monoclonal antibodies using its
SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the
potency of existing antibody products while opening new markets and disease applications
with other forms of SuperAntibodies. InNexus will develop the technology through
partnerships with biotechnology and pharmaceutical companies while pursuing development of
its own products for unmet medical needs. “Over the last 30
years, it has been proven that you can make drugs from monoclonal antibodies and that
these drugs can probably be more useful than traditional drugs in treating different kinds
of diseases.” Offers, Dr. Charles A. Morgan,
President and Director of InNexus Biotechnology, “Currently,
monoclonal antibodies do about three billion dollars a year in sales. It has gone from a
great concept to a proven commercial approach in making drugs. What we do is improve the
therapeutic activity of monoclonal antibodies. There are two big impacts of that;
obviously the first means that we can treat diseases better with monoclonal antibodies and
probably more importantly, it means that we can get them approved as drugs more readily.
They have a much higher likelihood of being approved as a SuperAntibody rather than a
regular monoclonal antibody.” Commenting on InNexus position in the industry, Dr. Morgan tells us, “We are alone with
regard to producing SuperAntibodies. There are other technologies that may allow you to
increase potency of antibodies but they rely upon putting toxic agents onto the antibody.
You can tether to an antibody, a drug, protein toxin or isotope. The conjugated antibody
may then be able to kill or treat the cells for which it is targeted. There are a number
of platform technologies out there that do that and seek to take an antibody that binds
and selects the target well, and then turn it into a therapeutically effective antibody.
They all rely upon using toxic substances; our technology instead installs a simple,
non-toxic peptide into an antibody and allows the antibodies to link arm-in-arm across the
surface of a cell. That appears to be sufficient to trigger the death of a targeted
cell.” Asked to share some thoughts on their business Dr.
Morgan says, “Our business is an out-licensing business.
It is not a small undertaking because the types of companies we work with are on the
leading edge of the monoclonal antibody field and their partners are at the leading edge
of pharmaceutical drug development. We license out our technology and have an ongoing role
in not only making these SuperAntibodies and developing them through clinical trials and
marketing. We may even form joint development agreements with Companies for products we
feel we can add more to than just technology enhancement. A Company may come to us with an
antibody that they know can detect and bind to a disease and for which they would like a
more therapeutically active version. We create a SuperAntibody version, have it evaluated
in both our labs and theirs and then proceed into the development of the product and
through clinical trials. We don’t actually do the clinical development ourselves; we
rely on our partners to do that. We are more involved at the early stages of the
product’s development.” Addressing investors, Dr.
Morgan comments, “The timetable for investment is now
which is based on announcements we will be able to make over the next year. Obviously we
believe that the announcements that we are going to make in the coming year, will
certainly be perceived as adding value to the company and they are all related to our
licensing business. It is different when you are announcing progress in preclinical
development and clinical development of a product. Those are certainly very good
milestones for the company. What we announcements is announce will be relationships, which
not only bring cash to us but essentially fund the development of our products through our
partners. I think people will appreciate the value that is coming from that and we have a
number of those types of announcements coming this year.” |
|
|
|
To view Releases highlight & left click on the company name!
|
|
